Folate supplementation during methotrexate therapy for patients with psoriasis

被引:67
作者
Strober, BE
Menon, K
机构
[1] NYU, Sch Med, Dept Dermatol, New York, NY USA
[2] NYU, Sch Med, Dept Dermatopharmacol, New York, NY USA
关键词
D O I
10.1016/j.jaad.2005.06.036
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Methotrexate is a folate antagonist that is a well-established therapy for autoimmune and inflammatory conditions. In some patients, methotrexate is associated with significant side effects and toxicity. Folate supplementation is often used to ameliorate methotrexate-associated side effects and toxicities. We sought to demonstrate that folate supplementation during methotrexate therapy reduces both toxicity and side effects without compromising efficacy. A MEDLINE search of the search terms "methotrexate," "folic acid," "folinic acid," and "leucovorin" was performed and literature relevant to the use of folates as a supplement to methotrexate was reviewed. According to studies reviewed, the use of folate supplements in patients treated with methotrexate reduces the incidence of hepatotoxicity and gastrointestinal intolerance without impairing the efficacy of methotrexate. Both folic acid and folinic acid are equally effective; however, folic acid is more cost effective. it must be noted that there are relatively few studies that have addressed folate supplementation with the use of methotrexate for the treatment of psoriasis. After examining the available data from the literature and drawing from clinical experience, we advise folate supplementation for every patient who receives methotrexate.
引用
收藏
页码:652 / 659
页数:8
相关论文
共 32 条
[1]   Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis [J].
Baggott, JE ;
Morgan, SL ;
Sams, WM ;
Linden, J .
ARCHIVES OF DERMATOLOGY, 1999, 135 (07) :813-817
[2]   Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease [J].
Boers, GHJ .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (03) :291-295
[3]   Molecular action of methotrexate in inflammatory diseases [J].
Chan, ESL ;
Cronstein, BN .
ARTHRITIS RESEARCH, 2002, 4 (04) :266-273
[4]   Molecular therapeutics - Methotrexate and its mechanism of action [J].
Cronstein, BN .
ARTHRITIS AND RHEUMATISM, 1996, 39 (12) :1951-1960
[5]  
*DRUGST COM, DRUG PRIC INF
[7]   Immunosuppressive agents in dermatology - An update [J].
Dutz, JP ;
Ho, VC .
DERMATOLOGIC CLINICS, 1998, 16 (02) :235-+
[8]  
Endresen GKM, 2001, SCAND J RHEUMATOL, V30, P129, DOI 10.1080/030097401300162888
[9]   Other novel immunosuppressants [J].
Flores, F ;
Kerdel, FA .
DERMATOLOGIC CLINICS, 2000, 18 (03) :475-+
[10]   Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? [J].
Griffith, SM ;
Fisher, J ;
Clarke, S ;
Montgomery, B ;
Jones, PW ;
Saklatvala, J ;
Dawes, PT ;
Shadforth, MF ;
Hothersall, TE ;
Hassell, AB ;
Hay, EM .
RHEUMATOLOGY, 2000, 39 (10) :1102-1109